Takeda Pharmaceutical Company Limited
TSE-4502
Company Overview
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan, the United States, Europe, Canada, Latin America, Russia, rest of Asia, and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab, Alofisel, Dexilant, Natpara, Adynovate/Adynovi, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Velcade, Leuplin/Enantone, Adcetris, Vyvansese, Trintellix, and Alunbrig brands. Takeda Pharmaceutical Company Limited has out-licensing agreement with Neurocrine Biosciences, Inc.; collaborations and in-licensing agreements with the University of Texas MD Anderson Cancer Center, Arrowhead Pharmaceuticals Inc., and Ovid Therapeutics Inc.; and collaboration with Evox Therapeutics Ltd., as well as a licensing agreement with ProThera Biologics Inc. It also has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, Selecta Biosciences, BridGene Biosciences, Skyhawk Therapeutics, and StrideBio; and strategic alliances with Egle Therapeutics SAS; Evotec SE; Neurocrine Biosciences, Inc.; Carmine Therapeutics; KSQ Therapeutics; and Anima Biotech. Takeda Pharmaceutical Company Limited was founded in 1781 and is headquartered in Tokyo, Japan.
Name
Takeda Pharmaceutical Company Limited
CEO
Mr. Christophe Weber
Website
www.takeda.com
Sector
Pharmaceuticals
Year Founded
1781
Profile
Market Cap
¥6,762.6B
EV
¥12.06T
Shares Out
1,584.86M
Revenue
¥4,413.13B
Employees
49,281
Margins
Gross
66.07%
EBITDA
26.61%
Operating
11.54%
Pre-Tax
1.23%
Net
3.4%
FCF
13.76%
Returns (5Yr Avg)
ROA
1.69%
ROTA
17.3%
ROE
4.06%
ROCE
4.43%
ROIC
-7.87%
Valuation (TTM)
P/E
—
P/B
—
EV/Sales
—
EV/EBITDA
—
P/FCF
—
EV/Gross Profit
—
Valuation (NTM)
Price Target
¥4,768.83
P/E
—
PEG
—
EV/Sales
—
EV/EBITDA
—
P/FCF
—
Financial Health
Cash
¥804.27B
Net Debt
¥5,293.1B
Debt/Equity
0.78
EBIT/Interest
4.41
Growth (CAGR)
Rev 3Yr
9.67%
Rev 5Yr
12.07%
Rev 10Yr
10.06%
Dil EPS 3Yr
-29.84%
Dil EPS 5Yr
11.39%
Dil EPS 10Yr
-3.27%
Rev Fwd 2Yr
2.3%
EBITDA Fwd 2Yr
13.84%
EPS Fwd 2Yr
28.18%
EPS LT Growth Est
12.41%
Dividends
Yield
—
Payout
196.64%
DPS
¥188
DPS Growth 3Yr
1.46%
DPS Growth 5Yr
0.87%
DPS Growth 10Yr
0.44%
DPS Growth Fwd 2Yr
3.37%